Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.84
(
-1.80%
)
Bitcoin
74,307.33
(
0.49%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: wallstarb post# 84961

Monday, 10/12/2009 6:47:14 PM

Monday, October 12, 2009 6:47:14 PM

Post# of 257253

VNDA probrably spent near $200m over the last XX years developing [Iloperidone]…

How do you figure that? I would guess that VNDA’s development expenses have been a small fraction of your figure.

why wouldnt [VNDA] publish the revenue share?

This deal does not have revenue sharing, but rather royalties on sales. The royalty terms in these kinds of deals are rarely disclosed.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now